MapLight Therapeutics Overview
MapLight Therapeutics (MPLT) has a P/E ratio of -1.9, below the Healthcare sector average of 25.72.
Get informed when a big investor buys or sells
+ Follow-1.90
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
MapLight Therapeutics (MPLT) currently reports a P/E ratio of -1.9. That is below the Healthcare sector average of 25.72. Use the charts on this page to explore MapLight Therapeutics's P/E ratio history and peer comparisons.
MapLight Therapeutics's P/E ratio of -1.9 is lower than the Healthcare sector average of 25.72. That is roughly 107.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates MapLight Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -1.9, MPLT can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -1.9, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 25.72. From there, open related valuation or income-statement pages for MapLight Therapeutics, and consider following MPLT for alerts when major investors trade the stock.
MapLight Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -1.9 versus a sector average near 25.72. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing MPLT with unrelated industries.
